Shares of Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) have earned a consensus recommendation of “Hold” from the nineteen brokerages that are presently covering the firm. Four equities research analysts have rated the stock with a sell recommendation, four have given a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $173.55.

Several equities analysts have commented on ICPT shares. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating and set a $147.00 price objective on the stock in a report on Wednesday, October 26th. Oppenheimer Holdings, Inc. set a $200.00 price objective on shares of Intercept Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, January 11th. Wedbush reiterated an “outperform” rating and issued a $224.00 price objective on shares of Intercept Pharmaceuticals in a report on Thursday, November 3rd. Needham & Company LLC downgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 20th. Finally, Vetr upgraded shares of Intercept Pharmaceuticals from a “buy” rating to a “strong-buy” rating and set a $169.70 price objective on the stock in a report on Monday, January 9th.

This news story was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this news story on another domain, it was illegally copied and republished in violation of United States and international copyright and trademark legislation. The original version of this news story can be read at http://www.watchlistnews.com/brokerages-set-intercept-pharmaceuticals-inc-icpt-target-price-at-159-81/1121693.html.

In other Intercept Pharmaceuticals news, insider Lisa Bright sold 249 shares of the stock in a transaction dated Friday, November 25th. The shares were sold at an average price of $113.60, for a total transaction of $28,286.40. Following the sale, the insider now directly owns 18,209 shares in the company, valued at $2,068,542.40. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CMO David Shapiro sold 1,565 shares of the stock in a transaction dated Monday, January 9th. The stock was sold at an average price of $106.01, for a total transaction of $165,905.65. Following the sale, the chief marketing officer now owns 40,369 shares in the company, valued at $4,279,517.69. The disclosure for this sale can be found here. Insiders sold 7,904 shares of company stock worth $822,111 over the last 90 days. 9.20% of the stock is currently owned by corporate insiders.

Large investors have recently made changes to their positions in the company. Schwab Charles Investment Management Inc. increased its stake in shares of Intercept Pharmaceuticals by 19.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 56,429 shares of the biopharmaceutical company’s stock worth $8,052,000 after buying an additional 9,112 shares during the last quarter. Amalgamated Bank increased its stake in shares of Intercept Pharmaceuticals by 39.0% in the second quarter. Amalgamated Bank now owns 2,619 shares of the biopharmaceutical company’s stock worth $413,000 after buying an additional 735 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Intercept Pharmaceuticals by 4.5% in the second quarter. Legal & General Group Plc now owns 1,196 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 52 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in shares of Intercept Pharmaceuticals by 3.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 1,234 shares of the biopharmaceutical company’s stock worth $176,000 after buying an additional 38 shares during the last quarter. Finally, RTW Investments LLC purchased a new stake in shares of Intercept Pharmaceuticals during the second quarter worth about $5,636,000. Hedge funds and other institutional investors own 82.28% of the company’s stock.

Intercept Pharmaceuticals (NASDAQ:ICPT) opened at 129.85 on Tuesday. The company’s market capitalization is $3.22 billion. Intercept Pharmaceuticals has a 52 week low of $96.63 and a 52 week high of $177.93. The firm has a 50 day moving average of $111.59 and a 200-day moving average of $130.35.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

5 Day Chart for NASDAQ:ICPT

Receive News & Ratings for Intercept Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.